Expression of microRNAs in urinary bladder samples obtained from dogs with grossly normal bladders, inflammatory bladder disease, or transitional cell carcinoma

American Journal of Veterinary Research

Volumn 73, Issue 10, 2012, Pages 1626-1633

  Vinall, Ruth L ^a,b   Kent, Michael S ^c   deVere White, Ralph W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA NORTHSTATE UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; MICRORNA; MICRORNA 103B; MICRORNA 106B; MICRORNA 16; MICRORNA 34A; MICRORNA LET 7C; MITOXANTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLADDER; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYSTITIS; DOG; DRUG EFFECT; FEMALE; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CELL LINE; CELL PROLIFERATION; CISPLATIN; CYSTITIS; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION; MALE; MICRORNAS; REAL-TIME POLYMERASE CHAIN REACTION; URINARY BLADDER; URINARY BLADDER DISEASES; URINARY BLADDER NEOPLASMS;

CANIS FAMILIARIS;

EID: 84867091563     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.73.10.1626     Document Type: Article

References (63)

1. Norris AM, Laing EJ, Valli VE, et al. Canine bladder and urethral tumors: a retrospective study of 115 cases (1980-1985). J Vet Intern Med 1992;6:145-153.
2. Priester WA, McKay FW. The occurrence of tumors in domestic animals. Natl Cancer Inst Monogr 1980;54:1-210.
3. Mutsaers AJ, Widmer WR, Knapp DW. Canine transitional cell carcinoma. J Vet Intern Med 2003;17:136-144.
4. Glickman LT, Raghavan M, Knapp DW, et al. Herbicide exposure and the risk of transitional cell carcinoma of the urinary bladder in Scottish Terriers. J Am Vet Med Assoc 2004;224:1290-1297.
5. Glickman LT, Schofer FS, McKee LJ, et al. Epidemiologic study of insecticide exposures, obesity, and risk of bladder cancer in household dogs. J Toxicol Environ Health 1989;28:407-414.
6. Owen LN. TNM classification of tumours in domestic animals. Geneva: World Health Organization, 1980;32-34.
7. Knapp DW, Glickman NW, Denicola DB, et al. Naturally-occurring canine transitional cell carcinoma of the urinary bladder A relevant model of human invasive bladder cancer. Urol Oncol 2000;5:47-59.
8. Boria PA, Glickman NW, Schmidt BR, et al. Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. Vet Comp Oncol 2005;3:73-80.
9. Chun R, Knapp DW, Widmer WR, et al. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993). J Am Vet Med Assoc 1996;209:1588-1591.
10. Greene SN, Lucroy MD, Greenberg CB, et al. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder. J Am Vet Med Assoc 2007;231:1056-1060.
11. Mohammed SI, Craig BA, Mutsaers AJ, et al. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol Cancer Ther 2003;2:183-188.
12. Shapiro W, Kitchell BE, Fossum TW, et al. Cisplatin for treatment of transitional cell and squamous cell carcinomas in dogs. J Am Vet Med Assoc 1988;193:1530-1533.
13. Poirier VJ, Forrest LJ, Adams WM, et al. Piroxicam, mitoxantrone, and coarse fraction radiotherapy for the treatment of transitional cell carcinoma of the bladder in 10 dogs: a pilot study. J Am Anim Hosp Assoc 2004;40:131-136.
14. Upton ML, Tangner CH, Payton ME. Evaluation of carbon dioxide laser ablation combined with mitoxantrone and piroxicam treatment in dogs with transitional cell carcinoma. J Am Vet Med Assoc 2006;228:549-552.
15. Bilbrey SA, Withrow SJ, Klein MK, et al. Vulvovaginectomy and perineal urethrostomy for neoplasms of the vulva and vagina. Vet Surg 1989;18:450-453.
16. Horninger W, Berger A, Pelzer A, et al. Screening for prostate cancer: updated experience from the Tyrol study. Curr Urol Rep 2004;5:220-225.
17. Djavan B, Eckersberger E, Finkelstein J, et al. Prostate-specific antigen testing and prostate cancer screening. Prim Care 2010;37:441-459.
18. Chu LL, Weinstein S, Yee J. Colorectal cancer screening in women: an underutilized lifesaver. AJR Am J Roentgenol 2011;196:303-310.
19. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-573.
20. Nelson HD, Tyne K, Naik A, et al. Screening for breast cancer: an update for the US Preventive Services Task Force. Ann Intern Med 2009;151:727-737.
21. Henry CJ. Management of transitional cell carcinoma. Vet Clin North Am Small Anim Pract 2003;33:597-613.
22. Anderson WI, Dunham BM, King JM, et al. Presumptive sub-cutaneous surgical transplantation of a urinary bladder transitional cell carcinoma in a dog. Cornell Vet 1989;79:263-266.
23. Vignoli M, Rossi F, Chierici C, et al. Needle tract implantation after fine needle aspiration biopsy (FNAB) of transitional cell carcinoma of the urinary bladder and adenocarcinoma of the lung. Schweiz Arch Tierheilkd 2007;149:314-318.
24. Henry CJ, Tyler JW, McEntee MC, et al. Evaluation of a bladder tumor antigen test as a screening test for transitional cell carcinoma of the lower urinary tract in dogs. Am J Vet Res 2003;64:1017-1020.
25. Soifer HS, Rossi JJ, Saetrom P. MicroRNAs in disease and potential therapeutic applications. Mol Ther 2007;15:2070-2079.
26. Xie X, Lu J, Kulbokas EJ, et al. Systematic discovery of regulatory motifs in human promoters and 3mmUTRs by comparison of several mammals. Nature 2005;434:338-345.
27. Cowland JB, Hother C, Gronbaek K. MicroRNAs and cancer. APMIS 2007;115:1090-1106.
28. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004.
29. Huppi K, Volfovsky N, Mackiewicz M, et al. MicroRNAs and genomic instability. Semin Cancer Biol 2007;17:65-73.
30. Wu W, Sun M, Zou GM, et al. MicroRNA and cancer: current status and prospective. Int J Cancer 2007;120:953-960.
31. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-866.
32. Tagawa H, Karube K, Tsuzuki S, et al. Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development. Cancer Sci 2007;98:1482-1490.
33. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene 2007;26:2799-2803.
34. Voorhoeve PM, le Sage C, Schrier M, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006;124:1169-1181.
35. Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008;40:43-50.
36. Lee DY, Deng Z, Wang CH, et al. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci U S A 2007;104:20350-20355.
37. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99:15524-15529.
38. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-833.
39. Vinall RL, Ripoll AZ, Wang S, et al. MiR-34 chemosensitizes bladder cancer cells to cisplatin regardless of p53-Rb pathway status. Int J Cancer 2012;130:2526-2538.
40. Jay C, Nemunaitis J, Chen P, et al. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol 2007;26:293-300.
41. Nelson PT, Baldwin DA, Scearce LM, et al. Microarray-based, high-throughput gene expression profiling of microRNAs. Nat Methods 2004;1:155-161.
42. Nuovo GJ. In situ detection of precursor and mature micro-RNAs in paraffin embedded, formalin fixed tissues and cell preparations. Methods 2008;44:39-46.
43. Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol [serial online] 2007;7:36. Available at: www.biomedcentral.com/1472-6750/7/36. Accessed May 5, 2011.
44. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-838.
45. Knapp DW, Richardson RC, Bottoms GD, et al. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 1992;29:214-218.
46. Knapp DW, Richardson RC, Chan TC, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.
47. Dhawan D, Ramos-Vara JA, Stewart JC, et al. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer. Urol Oncol 2009;27:284-292.
48. Meyer SU, Pfaffl MW, Ulbrich SE. Normalization strategies for microRNA profiling experiments: a 'normal' way to a hidden layer of complexity? Biotechnol Lett 2010;32:1777-1788.
49. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T) method. Methods 2001;25:402-408.
50. Boggs RM, Wright ZM, Stickney MJ, et al. MicroRNA expression in canine mammary cancer. Mamm Genome 2008;19:561-569.
51. Zhang L, Huang J, Yang N, et al. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 2006;103:9136-9141.
52. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-7070.
53. Mattie MD, Benz CC, Bowers J, et al. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006;5:24.
54. Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-2261.
55. Yan LX, Huang XF, Shao Q, et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008;14:2348-2360.
56. Bottoni A, Piccin D, Tagliati F, et al. miR-15a and miR-16-1 downregulation in pituitary adenomas. J Cell Physiol 2005;204:280-285.
57. Wang C, Bian Z, Wei D, et al. miR-29b regulates migration of human breast cancer cells. Mol Cell Biochem 2011;352:197-207.
58. Bonci D, Coppola V, Musumeci M, et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008;14:1271-1277.
59. Pan X, Wang ZX, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther 2011;10:1224-1232.
60. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007;6:60.
61. Zhang Y, Yan LX, Wu QN, et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 protooncogene in human invasive breast cancer. Cancer Res 2011;71:3552-3562.
62. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010;17:193-199.
63. Mizuno H, Nakamura A, Aoki Y, et al. Identification of musclespecific microRNAs in serum of muscular dystrophy animal models: promising novel blood-based markers for muscular dystrophy. PLoS One [serial online] 2011;6:e18388. Available at: www.plosone.org/article/info:doi/10.1371/journal. pone.0018388. Accessed May 5, 2011.